Viatris (VTRS) Competitors

Takeda Pharmaceutical pays an annual dividend of $0.48 per share and has a dividend yield of 2.6%. Viatris pays an annual dividend of $0.48 per share and has a dividend yield of 3.0%. Takeda Pharmaceutical pays out 141.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Viatris pays out -133.3% of its earnings in the form of a dividend. Viatris is clearly the better dividend stock, given its higher yield and lower payout ratio.

Takeda Pharmaceutical has a beta of -0.08, meaning that its share price is 108% less volatile than the broader market. Comparatively, Viatris has a beta of 0.9, meaning that its share price is 10% less volatile than the broader market.

Takeda Pharmaceutical has a net margin of 3.80% compared to Viatris' net margin of -2.79%. Viatris' return on equity of 20.02% beat Takeda Pharmaceutical's return on equity.

Takeda Pharmaceutical has higher revenue and earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Viatris has a consensus price target of $17.50, suggesting a potential upside of 7.69%. Given Viatris' stronger consensus rating and higher possible upside, analysts plainly believe Viatris is more favorable than Takeda Pharmaceutical.

In the previous week, Takeda Pharmaceutical had 3 more articles in the media than Viatris. MarketBeat recorded 4 mentions for Takeda Pharmaceutical and 1 mentions for Viatris. Viatris' average media sentiment score of 1.00 beat Takeda Pharmaceutical's score of 0.16 indicating that Viatris is being referred to more favorably in the news media.

9.2% of Takeda Pharmaceutical shares are owned by institutional investors. Comparatively, 79.9% of Viatris shares are owned by institutional investors. 0.0% of Takeda Pharmaceutical shares are owned by company insiders. Comparatively, 0.3% of Viatris shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. Comparatively, 79.9% of Viatris shares are held by institutional investors. 0.5% of Teva Pharmaceutical Industries shares are held by company insiders. Comparatively, 0.3% of Viatris shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Teva Pharmaceutical Industries has a beta of 0.86, meaning that its share price is 14% less volatile than the broader market. Comparatively, Viatris has a beta of 0.9, meaning that its share price is 10% less volatile than the broader market.

Teva Pharmaceutical Industries currently has a consensus price target of $42.22, suggesting a potential upside of 12.60%. Viatris has a consensus price target of $17.50, suggesting a potential upside of 7.69%. Given Teva Pharmaceutical Industries' stronger consensus rating and higher possible upside, equities research analysts clearly believe Teva Pharmaceutical Industries is more favorable than Viatris.

In the previous week, Teva Pharmaceutical Industries had 8 more articles in the media than Viatris. MarketBeat recorded 9 mentions for Teva Pharmaceutical Industries and 1 mentions for Viatris. Viatris' average media sentiment score of 1.00 beat Teva Pharmaceutical Industries' score of 0.71 indicating that Viatris is being referred to more favorably in the news media.

Teva Pharmaceutical Industries has higher revenue and earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Teva Pharmaceutical Industries has a net margin of 4.08% compared to Viatris' net margin of -2.79%. Teva Pharmaceutical Industries' return on equity of 32.64% beat Viatris' return on equity.

BeOne Medicines has higher earnings, but lower revenue than Viatris. Viatris is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

BeOne Medicines currently has a consensus price target of $402.14, suggesting a potential upside of 6.71%. Viatris has a consensus price target of $17.50, suggesting a potential upside of 7.69%. Given Viatris' higher probable upside, analysts plainly believe Viatris is more favorable than BeOne Medicines.

In the previous week, BeOne Medicines had 8 more articles in the media than Viatris. MarketBeat recorded 9 mentions for BeOne Medicines and 1 mentions for Viatris. Viatris' average media sentiment score of 1.00 beat BeOne Medicines' score of 0.43 indicating that Viatris is being referred to more favorably in the news media.

BeOne Medicines has a beta of 0.49, indicating that its share price is 51% less volatile than the broader market. Comparatively, Viatris has a beta of 0.9, indicating that its share price is 10% less volatile than the broader market.

BeOne Medicines has a net margin of 10.70% compared to Viatris' net margin of -2.79%. Viatris' return on equity of 20.02% beat BeOne Medicines' return on equity.

48.6% of BeOne Medicines shares are held by institutional investors. Comparatively, 79.9% of Viatris shares are held by institutional investors. 6.2% of BeOne Medicines shares are held by company insiders. Comparatively, 0.3% of Viatris shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Viatris currently has a consensus target price of $17.50, suggesting a potential upside of 7.69%. Royalty Pharma has a consensus target price of $60.86, suggesting a potential downside of 1.41%. Given Viatris' higher probable upside, equities research analysts plainly believe Viatris is more favorable than Royalty Pharma.

Royalty Pharma has a net margin of 32.14% compared to Viatris' net margin of -2.79%. Royalty Pharma's return on equity of 30.01% beat Viatris' return on equity.

79.9% of Viatris shares are owned by institutional investors. Comparatively, 54.4% of Royalty Pharma shares are owned by institutional investors. 0.3% of Viatris shares are owned by company insiders. Comparatively, 18.8% of Royalty Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Viatris pays an annual dividend of $0.48 per share and has a dividend yield of 3.0%. Royalty Pharma pays an annual dividend of $0.94 per share and has a dividend yield of 1.5%. Viatris pays out -133.3% of its earnings in the form of a dividend. Royalty Pharma pays out 64.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Royalty Pharma has raised its dividend for 5 consecutive years. Viatris is clearly the better dividend stock, given its higher yield and lower payout ratio.

Royalty Pharma has lower revenue, but higher earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks.

Viatris has a beta of 0.9, indicating that its stock price is 10% less volatile than the broader market. Comparatively, Royalty Pharma has a beta of 0.43, indicating that its stock price is 57% less volatile than the broader market.

In the previous week, Royalty Pharma had 6 more articles in the media than Viatris. MarketBeat recorded 7 mentions for Royalty Pharma and 1 mentions for Viatris. Royalty Pharma's average media sentiment score of 1.03 beat Viatris' score of 1.00 indicating that Royalty Pharma is being referred to more favorably in the news media.